vs
联拓生物（CNTB）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
联拓生物的季度营收约是RIVERVIEW BANCORP INC的1.7倍（$24.1M vs $14.0M），联拓生物净利率更高（61.6% vs 9.8%，领先51.8%）
联拓生物是一家临床阶段的全球性生物制药企业，专注于研发针对炎症、免疫及自身免疫类疾病的创新靶向疗法，核心管线覆盖哮喘、特应性皮炎等存在未满足医疗需求的适应症，业务布局覆盖中美及全球主要市场。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
CNTB vs RVSB — 直观对比
营收规模更大
CNTB
是对方的1.7倍
$14.0M
净利率更高
CNTB
高出51.8%
9.8%
损益表 — Q2 FY2024 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $24.1M | $14.0M |
| 净利润 | $14.8M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | 56.6% | 12.4% |
| 净利率 | 61.6% | 9.8% |
| 营收同比 | — | 10.4% |
| 净利润同比 | 148.7% | 11.8% |
| 每股收益（稀释后） | $0.27 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CNTBRVSB
| Q4 25 | — | $14.0M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $13.3M | ||
| Q1 25 | — | $12.9M | ||
| Q4 24 | — | $12.7M | ||
| Q3 24 | — | $12.8M | ||
| Q2 24 | $24.1M | $12.2M | ||
| Q1 24 | — | $9.0M |
净利润CNTBRVSB
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $14.8M | $966.0K | ||
| Q1 24 | — | $-3.0M |
营业利润率CNTBRVSB
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | — | 11.7% | ||
| Q1 25 | — | 11.3% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | — | 15.5% | ||
| Q2 24 | 56.6% | 10.0% | ||
| Q1 24 | — | -47.5% |
净利率CNTBRVSB
| Q4 25 | — | 9.8% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 9.2% | ||
| Q1 25 | — | 8.9% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | — | 12.2% | ||
| Q2 24 | 61.6% | 7.9% | ||
| Q1 24 | — | -34.7% |
每股收益（稀释后）CNTBRVSB
| Q4 25 | — | $0.07 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | — | $0.06 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | — | $0.07 | ||
| Q2 24 | $0.27 | $0.05 | ||
| Q1 24 | — | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.2M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $110.9M | $164.2M |
| 总资产 | $120.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CNTBRVSB
| Q4 25 | — | $28.6M | ||
| Q3 25 | — | $32.8M | ||
| Q2 25 | — | $34.2M | ||
| Q1 25 | — | $29.4M | ||
| Q4 24 | — | $25.3M | ||
| Q3 24 | — | $31.0M | ||
| Q2 24 | $110.2M | $27.8M | ||
| Q1 24 | — | $23.6M |
股东权益CNTBRVSB
| Q4 25 | — | $164.2M | ||
| Q3 25 | — | $163.5M | ||
| Q2 25 | — | $162.0M | ||
| Q1 25 | — | $160.0M | ||
| Q4 24 | — | $158.3M | ||
| Q3 24 | — | $160.8M | ||
| Q2 24 | $110.9M | $155.9M | ||
| Q1 24 | — | $155.6M |
总资产CNTBRVSB
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $120.6M | $1.5B | ||
| Q1 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.0M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-736.0K |
| 自由现金流率自由现金流/营收 | — | -5.2% |
| 资本支出强度资本支出/营收 | — | 1.6% |
| 现金转化率经营现金流/净利润 | -0.54× | -0.37× |
| 过去12个月自由现金流最近4个季度 | — | $20.4M |
8季度趋势，按日历期对齐
经营现金流CNTBRVSB
| Q4 25 | — | $-506.0K | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $-697.0K | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $764.0K | ||
| Q2 24 | $-8.0M | $5.4M | ||
| Q1 24 | — | $12.8M |
自由现金流CNTBRVSB
| Q4 25 | — | $-736.0K | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $-773.0K | ||
| Q1 25 | — | $5.6M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | $7.1M |
自由现金流率CNTBRVSB
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 120.1% | ||
| Q2 25 | — | -5.8% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | — | 15.0% | ||
| Q3 24 | — | -11.3% | ||
| Q2 24 | — | 43.7% | ||
| Q1 24 | — | 79.0% |
资本支出强度CNTBRVSB
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 21.0% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 17.3% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 62.0% |
现金转化率CNTBRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | -0.54× | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
